GSK 3342830

Drug Profile

GSK 3342830

Alternative Names: GSK3342830

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shionogi
  • Developer GlaxoSmithKline; Shionogi
  • Class Anti-infectives; Antibacterials; Cephalosporins; Cephems
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gram-negative infections

Most Recent Events

  • 30 Nov 2017 GlaxoSmithKline terminates a phase I trial in Gram-negative infections (In volunteers) in Australia as study data is currently under review (IV) (NCT02751424)
  • 15 Mar 2017 GlaxoSmithKline suspends participant recruitment in a phase I trial in Gram-negative infections (In volunteers) in Australia (IV) (NCT02751424)
  • 01 Jun 2016 Phase-I clinical trials in Gram-negative infections (In volunteers) in Australia (IV) (NCT02751424)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top